Table 3.
Different agents and their targets in clinical trial.
| Classification | Agents | Targets | Phase | References |
|---|---|---|---|---|
| Traditional drug therapy | VC005 Tablets | JAK1 | Phase 1 | Clinicaltrials.gov |
| LNK01001 Capsule | JAK1 | Phase 2 | Clinicaltrials.gov | |
| Nano drug delivery system | TS-152 | TNF-α and serum albumin | Phase3 | Clinicaltrials.gov |
| long-circulating liposomal prednisolone | synovial tissue | Phase 2 | Clinicaltrials.gov | |
| Biological agents | VDJ001 | IL-6 | Phase 2 | Clinicaltrials.gov |
| Abatacept | Memory B Cells | Phase4 | Clinicaltrials.gov | |
| Cell therapy | Autologous Tolerogenic Dendritic Cells | none | Phase 1 | Clinicaltrials.gov |
| Mesenchymal Stem Cell Secretome | none | Phase 1/Phase 2 | Clinicaltrials.gov | |
| Traditional Chinese medicine | 2-HOBA | isolevuglandins | Phase 2 | Clinicaltrials.gov |
| Ursodeoxycholic Acid | synovial inflammation | Phase 2 | Clinicaltrials.gov | |
| Vaccine | COVID-19 Vaccine | none | Phase4 | Clinicaltrials.gov |
| Recombinant Herpes Zoster Vaccine | none | Phase4 | Clinicaltrials.gov | |
| Gene therapy | ART-I02 | IFN-β | Phase 1 | Clinicaltrials.gov |
| tgAAC94 | TNFR: Fc | Phase 1/Phase 2 | Clinicaltrials.gov |